Weight Gain After Switch from Efavirenz-Based to Integrase Inhibitor-Based Regimens

BACKGROUND: Integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) offers persons living with HIV a potent new treatment option. Recently, local HIV clinicians noted weight gain in patients who switched from daily, fixed-dose efavirenz/tenofovir disoproxil fumarate/emtricitab...

Descripción completa

Detalles Bibliográficos
Autores principales: Norwood, Jamison, Turner, Megan, Bofill, Carmen, Jenkins, Cathy, Bebawy, Sally, Rebeiro, Peter, Hulgan, Todd, Raffanti, Stephen, Haas, David, Sterling, Timothy R, Koethe, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631481/
http://dx.doi.org/10.1093/ofid/ofx163.1094

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5631481/
http://dx.doi.org/10.1093/ofid/ofx163.1094

Ejemplares similares